# Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)

> **NCT07204327** · — · ACTIVE_NOT_RECRUITING · sponsor: **Zhongda Hospital** · enrollment: 1136 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **OTHER:** Atezo+Bev plus Locoregional Therapy

## Key facts

- **NCT ID:** NCT07204327
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-28
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1136 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07204327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07204327, "Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07204327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*